Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Purpose
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
Conditions
- Mitral Regurgitation
- Mitral Insufficiency
- Mitral Valve Insufficiency
- Cardiovascular Diseases
- Valve Disease, Heart
- Heart Valve Diseases
- Functional Mitral Regurgitation
- Degenerative Mitral Valve Disease
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Symptomatic, moderate-to-severe or severe mitral regurgitation, or severe mitral annular calcification (MAC) - NYHA Functional Classification ≥ II (if Class IV, patient must be ambulatory) - The local site heart team determines that the subject has been adequately treated per applicable standards - Not a member of a vulnerable population
Exclusion Criteria
- Mitral valvular vegetation or mass - Left ventricular ejection fraction < 25% - Left ventricular end diastolic diameter > 7.0 cm - Prior surgical or interventional treatment of mitral valve involving implantation of prosthetic material - Aortic valve disease requiring surgery or transcatheter intervention - Severe tricuspid regurgitation or any tricuspid valve disease requiring surgery or transcatheter intervention - Any planned surgical / interventional procedure within 60 day prior to or following subject randomization - Subject undergoing hemodialysis due to chronic renal failure - Mitral pathoanatomy and left ventricular outflow tract anatomy deemed not suitable for Trial device implantation - Subjects with non-cardiac comorbidities that are likely to result in a life expectancy of less than 12 months
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Randomized Cohort - Treatment Group |
Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System |
|
|
Active Comparator Randomized Cohort - Control Group |
Treatment of mitral regurgitation within commercially approved MitraClip system indications |
|
|
Experimental Non-repairable Cohort |
Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System |
|
|
Experimental Severe Mitral Annular Calcification (MAC) Cohort |
Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System |
|
|
Experimental Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP) Cohort |
Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System after the completion of enrollment in the Severe MAC Cohort |
|
Recruiting Locations
Birmingham, Alabama 35233
Phoenix, Arizona 85006
Scottsdale, Arizona 85258
Little Rock, Arkansas 72205
Sacramento, California 95817
San Diego, California 92123
Stanford, California 94305
Thousand Oaks, California 91360
Clearwater, Florida 33756
Gainesville, Florida 32610
Tallahassee, Florida 32308
Weston, Florida 33331
Atlanta, Georgia 30309
Atlanta, Georgia 30322
Marietta, Georgia 30060
Oak Lawn, Illinois 60453
Indianapolis, Indiana 46260
Wichita, Kansas 67226
Balitmore, Maryland 21218
Ann Arbor, Michigan 48109
Minneapolis, Minnesota 55407
Rochester, Minnesota 55905
Missoula, Montana 59802
Hackensack, New Jersey 07601
New Brunswick, New Jersey 08901
Newark, New Jersey 07112
Albany, New York 12208
Bay Shore, New York 11706
Buffalo, New York 14203
New York, New York 10065
Asheville, North Carolina 28801
Charlotte, North Carolina 28203
Charlotte, North Carolina 28204
Cincinnati, Ohio 45219
Cleveland, Ohio 44195
Tulsa, Oklahoma 74104
Portland, Oregon 97225
Pittsburgh, Pennsylvania 15212
Pittsburgh, Pennsylvania 15232
Charleston, South Carolina 29425
Memphis, Tennessee 38120
Nashville, Tennessee 37203
Nashville, Tennessee 37205
Austin, Texas 78756
Houston, Texas 77030
Charlottesville, Virginia 22908
Seattle, Washington 98122
Morgantown, West Virginia 26506
More Details
- NCT ID
- NCT03433274
- Status
- Recruiting
- Sponsor
- Abbott Medical Devices